Logo for Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Investor Relations Material

Latest events

Logo for Crinetics Pharmaceuticals Inc

Q2 2024

Crinetics Pharmaceuticals
Logo for Crinetics Pharmaceuticals

Q2 2024

8 Aug, 2024
Logo for Crinetics Pharmaceuticals

Study Update

3 Jun, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Crinetics Pharmaceuticals Inc

Access all reports
Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that specializes in the development of novel therapeutics targeting peptide hormone receptors. Their focus is on the treatment of rare endocrine disorders and endocrine-related tumors. The company’s leading product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist. It is in advanced clinical trials for conditions such as acromegaly, carcinoid syndrome, and nonfunctional neuroendocrine tumors. Additionally, Crinetics Pharmaceuticals is developing other drug candidates for conditions like congenital hyperinsulinism and Cushing's disease. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.